Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shROR1 lentivirus is a gene therapy tool consisting of a lentiviral vector expressing short hairpin RNA (shRNA) designed to silence the expression of Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). ROR1 is a type I transmembrane protein often overexpressed in various malignancies, including glioblastoma (GBM) and glioma stem cells (GSCs), where it promotes tumorigenesis, self-renewal, and therapeutic resistance. By delivering shRNA into target cells, the lentivirus triggers the RNA interference (RNAi) pathway to degrade ROR1 mRNA, thereby inhibiting downstream signaling pathways such as the ROR1-GRB2-ERK-c-Fos axis. In preclinical models of glioblastoma, knockdown of ROR1 via this lentiviral approach has been shown to impair GSC proliferation and inhibit tumor growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shROR1 lentivirus.